Hyperprogression after nivolumab for the treatment of melanoma

Polak, Alexandra Perea; García, Silvestre Martínez; Díaz, Daniel Jesus Godoy.
Artículo | IMSEAR | ID: sea-223165

Documentos relacionados

  1. Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma.
  2. Hyperprogression after nivolumab for melanoma: A case report.
  3. Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
  4. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
  5. Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience.
  6. Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors.
  7. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
  8. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
  9. Squamous cell carcinoma or squamous proliferation associated with nivolumab treatment for metastatic melanoma.
  10. Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody.